WASHINGTON (MedPage Today) —Pharmacy groups are voicing their opposition to an amendment in the Senate’s FDA user fee reauthorization bill that would reclassify all medications containing hydrocodone as Schedule II drugs. MedPageToday.com –medical news plus CME for physicians












































